JP2005508336A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005508336A5 JP2005508336A5 JP2003530690A JP2003530690A JP2005508336A5 JP 2005508336 A5 JP2005508336 A5 JP 2005508336A5 JP 2003530690 A JP2003530690 A JP 2003530690A JP 2003530690 A JP2003530690 A JP 2003530690A JP 2005508336 A5 JP2005508336 A5 JP 2005508336A5
- Authority
- JP
- Japan
- Prior art keywords
- pyrrolidinyl
- piperazinyl
- alkyl
- morpholinyl
- pyridinyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 3-fluoropyrrolidinyl Chemical group 0.000 claims description 133
- 150000001875 compounds Chemical class 0.000 claims description 28
- 125000000217 alkyl group Chemical group 0.000 claims description 22
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
- 229910052736 halogen Inorganic materials 0.000 claims description 16
- 150000002367 halogens Chemical class 0.000 claims description 16
- 125000002757 morpholinyl group Chemical group 0.000 claims description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 13
- 125000004193 piperazinyl group Chemical group 0.000 claims description 12
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 12
- 125000003282 alkyl amino group Chemical group 0.000 claims description 10
- 229910052799 carbon Inorganic materials 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 7
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 150000001408 amides Chemical class 0.000 claims description 6
- 150000001412 amines Chemical class 0.000 claims description 6
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 claims description 6
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 6
- 150000003568 thioethers Chemical class 0.000 claims description 6
- KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 claims description 5
- 125000003118 aryl group Chemical group 0.000 claims description 5
- 229910052731 fluorine Inorganic materials 0.000 claims description 5
- ZCCPVTVGEQLONB-UHFFFAOYSA-N 1-(1,3-dioxolan-2-yl)-n-methylmethanamine Chemical compound CNCC1OCCO1 ZCCPVTVGEQLONB-UHFFFAOYSA-N 0.000 claims description 4
- QAFODUGVXFNLBE-UHFFFAOYSA-N 1-methoxybutan-2-amine Chemical compound CCC(N)COC QAFODUGVXFNLBE-UHFFFAOYSA-N 0.000 claims description 4
- ZUUQKDDUUOFCNP-UHFFFAOYSA-N 2-(1,3-dioxolan-2-yl)-n-methylethanamine Chemical compound CNCCC1OCCO1 ZUUQKDDUUOFCNP-UHFFFAOYSA-N 0.000 claims description 4
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 4
- 125000004364 3-pyrrolinyl group Chemical group [H]C1=C([H])C([H])([H])N(*)C1([H])[H] 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 claims description 4
- RZVWBASHHLFBJF-UHFFFAOYSA-N methyl piperidine-4-carboxylate Chemical compound COC(=O)C1CCNCC1 RZVWBASHHLFBJF-UHFFFAOYSA-N 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims description 4
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 claims description 3
- AHVQYHFYQWKUKB-UHFFFAOYSA-N oxan-4-amine Chemical compound NC1CCOCC1 AHVQYHFYQWKUKB-UHFFFAOYSA-N 0.000 claims description 3
- IPBPLHNLRKRLPJ-UHFFFAOYSA-N oxan-4-ylmethanamine Chemical compound NCC1CCOCC1 IPBPLHNLRKRLPJ-UHFFFAOYSA-N 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims 14
- 125000005647 linker group Chemical group 0.000 claims 10
- 239000000825 pharmaceutical preparation Substances 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 230000002062 proliferating effect Effects 0.000 claims 8
- 125000003386 piperidinyl group Chemical group 0.000 claims 7
- 206010016654 Fibrosis Diseases 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 125000001153 fluoro group Chemical group F* 0.000 claims 5
- 208000030159 metabolic disease Diseases 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 230000004761 fibrosis Effects 0.000 claims 4
- 210000003584 mesangial cell Anatomy 0.000 claims 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 4
- 230000002792 vascular Effects 0.000 claims 4
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 3
- 201000004681 Psoriasis Diseases 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 3
- 206010064930 age-related macular degeneration Diseases 0.000 claims 3
- 125000006309 butyl amino group Chemical group 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 208000002780 macular degeneration Diseases 0.000 claims 3
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 206010063209 Chronic allograft nephropathy Diseases 0.000 claims 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims 2
- 208000034841 Thrombotic Microangiopathies Diseases 0.000 claims 2
- 208000031737 Tissue Adhesions Diseases 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000007882 cirrhosis Effects 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 208000033679 diabetic kidney disease Diseases 0.000 claims 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 230000003211 malignant effect Effects 0.000 claims 2
- 201000009925 nephrosclerosis Diseases 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 208000037803 restenosis Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 230000029663 wound healing Effects 0.000 claims 2
- KDHWOCLBMVSZPG-UHFFFAOYSA-N 3-imidazol-1-ylpropan-1-amine Chemical compound NCCCN1C=CN=C1 KDHWOCLBMVSZPG-UHFFFAOYSA-N 0.000 claims 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32581501P | 2001-09-27 | 2001-09-27 | |
| US32581901P | 2001-09-27 | 2001-09-27 | |
| PCT/US2002/030882 WO2003027102A1 (en) | 2001-09-27 | 2002-09-27 | 3-(arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010013326A Division JP2010116411A (ja) | 2001-09-27 | 2010-01-25 | キナーゼ阻害物質としての３−（アリールアミノ）メチレン−１，３−ジヒドロ−２ｈ−インドール−２−オン類 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005508336A JP2005508336A (ja) | 2005-03-31 |
| JP2005508336A5 true JP2005508336A5 (enExample) | 2006-01-12 |
Family
ID=26985125
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003530690A Pending JP2005508336A (ja) | 2001-09-27 | 2002-09-27 | キナーゼ阻害物質としての３−（アリールアミノ）メチレン−１，３−ジヒドロ−２ｈ−インドール−２−オン類 |
| JP2010013326A Pending JP2010116411A (ja) | 2001-09-27 | 2010-01-25 | キナーゼ阻害物質としての３−（アリールアミノ）メチレン−１，３−ジヒドロ−２ｈ−インドール−２−オン類 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010013326A Pending JP2010116411A (ja) | 2001-09-27 | 2010-01-25 | キナーゼ阻害物質としての３−（アリールアミノ）メチレン−１，３−ジヒドロ−２ｈ−インドール−２−オン類 |
Country Status (6)
| Country | Link |
|---|---|
| US (7) | US20030225152A1 (enExample) |
| EP (1) | EP1430048A1 (enExample) |
| JP (2) | JP2005508336A (enExample) |
| AU (1) | AU2002341881B2 (enExample) |
| CA (1) | CA2461812C (enExample) |
| WO (1) | WO2003027102A1 (enExample) |
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998046588A2 (en) * | 1997-04-11 | 1998-10-22 | Neorx Corporation | Compounds and therapies for the prevention of vascular and non-vascular pathologies |
| US7164001B2 (en) * | 2000-01-20 | 2007-01-16 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| EP1415987B1 (en) | 2000-10-20 | 2007-02-28 | Eisai R&D Management Co., Ltd. | Nitrogenous aromatic ring compounds as anti cancer agents |
| US20030225152A1 (en) * | 2001-09-27 | 2003-12-04 | Andrews Steven W. | 3-(Arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors |
| US7169936B2 (en) | 2002-07-23 | 2007-01-30 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments |
| DE10233366A1 (de) * | 2002-07-23 | 2004-02-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | In 6-Stellung substituierte Indolinonderivate, ihre Herstellung und ihre Verwendung als Arzneimittel |
| US7514468B2 (en) | 2002-07-23 | 2009-04-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions |
| PE20040701A1 (es) * | 2002-07-23 | 2004-11-30 | Boehringer Ingelheim Pharma | Derivados de indolinona sustituidos en posicion 6 y su preparacion como medicamentos |
| WO2005044788A1 (ja) | 2003-11-11 | 2005-05-19 | Eisai Co., Ltd. | ウレア誘導体およびその製造方法 |
| US20070224278A1 (en) | 2003-11-12 | 2007-09-27 | Lyons Robert T | Low immunogenicity corticosteroid compositions |
| US20050101582A1 (en) | 2003-11-12 | 2005-05-12 | Allergan, Inc. | Compositions and methods for treating a posterior segment of an eye |
| CN100548271C (zh) | 2004-01-20 | 2009-10-14 | 阿勒根公司 | 用于眼部的局部治疗、并优选包括有曲安奈德及透明质酸的组合物 |
| US7338536B2 (en) | 2004-02-27 | 2008-03-04 | L'oreal S. A. | N-alkylamino secondary para-phenylenediamine, composition for dyeing keratin fibers comprising such a para-phenylenediamine, processes using this composition and uses thereof |
| FR2866879A1 (fr) * | 2004-02-27 | 2005-09-02 | Oreal | Para-phenylenediamine secondaire n-alkylaminee, composition de teinture des fibres keratiniques contenant une telle para-phenylenediamine, procedes mettant en oeuvre cette composition et utilisations |
| KR100629713B1 (ko) * | 2004-04-10 | 2006-09-29 | (주)아모레퍼시픽 | 펜타에리스리톨 유도체와 이의 제조방법, 및 이를포함하는 액정베이스 |
| US8673341B2 (en) | 2004-04-30 | 2014-03-18 | Allergan, Inc. | Intraocular pressure reduction with intracameral bimatoprost implants |
| US20050244458A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular neuropathies |
| US8722097B2 (en) | 2004-04-30 | 2014-05-13 | Allergan, Inc. | Oil-in-water method for making polymeric implants containing a hypotensive lipid |
| US7993634B2 (en) | 2004-04-30 | 2011-08-09 | Allergan, Inc. | Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods |
| US20050244461A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Controlled release drug delivery systems and methods for treatment of an eye |
| US8147865B2 (en) | 2004-04-30 | 2012-04-03 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
| US20050244472A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Intraocular drug delivery systems containing excipients with reduced toxicity and related methods |
| US20050244463A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
| US8455656B2 (en) | 2004-04-30 | 2013-06-04 | Allergan, Inc. | Kinase inhibitors |
| US8119154B2 (en) | 2004-04-30 | 2012-02-21 | Allergan, Inc. | Sustained release intraocular implants and related methods |
| US9498457B2 (en) | 2004-04-30 | 2016-11-22 | Allergan, Inc. | Hypotensive prostamide-containing biodegradable intraocular implants and related implants |
| US20050244466A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Photodynamic therapy in conjunction with intraocular implants |
| US20070059336A1 (en) * | 2004-04-30 | 2007-03-15 | Allergan, Inc. | Anti-angiogenic sustained release intraocular implants and related methods |
| US20050244478A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Anti-excititoxic sustained release intraocular implants and related methods |
| US8512738B2 (en) * | 2004-04-30 | 2013-08-20 | Allergan, Inc. | Biodegradable intravitreal tyrosine kinase implants |
| US8591885B2 (en) * | 2004-04-30 | 2013-11-26 | Allergan, Inc. | Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems |
| US20050244462A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Devices and methods for treating a mammalian eye |
| US20050244471A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Estradiol derivative and estratopone containing sustained release intraocular implants and related methods |
| US7771742B2 (en) * | 2004-04-30 | 2010-08-10 | Allergan, Inc. | Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods |
| US7799336B2 (en) | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
| US8425929B2 (en) | 2004-04-30 | 2013-04-23 | Allergan, Inc. | Sustained release intraocular implants and methods for preventing retinal dysfunction |
| ATE428421T1 (de) | 2004-09-17 | 2009-05-15 | Eisai R&D Man Co Ltd | Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften |
| TW200640443A (en) | 2005-02-23 | 2006-12-01 | Alcon Inc | Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors |
| US7749530B2 (en) | 2005-07-13 | 2010-07-06 | Allergan, Inc. | Kinase inhibitors |
| US7309787B2 (en) * | 2005-07-13 | 2007-12-18 | Allergan, Inc. | Kinase inhibitors |
| EP1902024B1 (en) | 2005-07-13 | 2013-04-17 | Allergan, Inc. | Kinase inhibitors |
| EP1902025A1 (en) | 2005-07-13 | 2008-03-26 | Allergan, Inc. | Kinase inhibitors |
| EP1925676A4 (en) | 2005-08-02 | 2010-11-10 | Eisai R&D Man Co Ltd | TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR |
| US8367664B2 (en) | 2006-01-24 | 2013-02-05 | Allergan, Inc. | Substituted 3-(5-membered unsaturated heterocyclyl-1, 3-dihydro-indol-2-one's and derivatives thereof as kinase inhibitors |
| US7977351B2 (en) * | 2006-03-22 | 2011-07-12 | Allergan, Inc. | Heteroaryl dihydroindolones as kinase inhibitors |
| WO2007136103A1 (ja) | 2006-05-18 | 2007-11-29 | Eisai R & D Management Co., Ltd. | 甲状腺癌に対する抗腫瘍剤 |
| WO2008022013A1 (en) * | 2006-08-11 | 2008-02-21 | Allergan, Inc. | Kinase inhibitors |
| KR101472600B1 (ko) | 2006-08-28 | 2014-12-15 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 미분화형 위암에 대한 항종양제 |
| US8143410B2 (en) | 2006-11-16 | 2012-03-27 | Allergan, Inc. | Kinase inhibitors |
| US8558002B2 (en) | 2006-11-16 | 2013-10-15 | Allergan, Inc. | Sulfoximines as kinase inhibitors |
| US8969415B2 (en) | 2006-12-01 | 2015-03-03 | Allergan, Inc. | Intraocular drug delivery systems |
| EP2119707B1 (en) | 2007-01-29 | 2015-01-14 | Eisai R&D Management Co., Ltd. | Composition for treatment of undifferentiated-type of gastric cancer |
| US8642067B2 (en) | 2007-04-02 | 2014-02-04 | Allergen, Inc. | Methods and compositions for intraocular administration to treat ocular conditions |
| US7911053B2 (en) * | 2007-04-19 | 2011-03-22 | Marvell World Trade Ltd. | Semiconductor packaging with internal wiring bus |
| DK2170827T3 (da) * | 2007-06-21 | 2013-11-18 | Janssen Pharmaceutica Nv | Indolin-2-oner og aza-indolin-2-oner |
| JP5209254B2 (ja) * | 2007-08-30 | 2013-06-12 | 日本曹達株式会社 | 置換フェノキシアザビシクロオクタン誘導体の製造方法 |
| CN101848895B (zh) | 2007-11-09 | 2013-10-23 | 卫材R&D管理有限公司 | 血管新生抑制物质和抗肿瘤性铂络合物的组合使用 |
| BR112012003592B8 (pt) | 2009-08-19 | 2021-05-25 | Eisai R&D Man Co Ltd | composição farmacêutica contendo derivado de quinolina |
| US9340555B2 (en) | 2009-09-03 | 2016-05-17 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
| US8614234B2 (en) | 2009-09-03 | 2013-12-24 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
| EP3421030A1 (en) | 2009-11-09 | 2019-01-02 | Allergan, Inc. | Compositions and methods for stimulating hair growth |
| CA2802644C (en) | 2010-06-25 | 2017-02-21 | Eisai R & D Management Co., Ltd. | Antitumor agent using compounds having kinase inhibitory effect in combination |
| EP2700403B1 (en) | 2011-04-18 | 2015-11-25 | Eisai R&D Management Co., Ltd. | Therapeutic agent for tumor |
| WO2012166899A2 (en) | 2011-06-03 | 2012-12-06 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| CN103304468A (zh) * | 2012-03-13 | 2013-09-18 | 华东师范大学 | 一种氧化吲哚的一锅法串联合成方法 |
| US9642851B2 (en) | 2012-12-06 | 2017-05-09 | Kbp Biosciences Co., Ltd. | Indolinone derivative as tyrosine kinase inhibitor |
| AU2013364953A1 (en) | 2012-12-21 | 2015-04-30 | Eisai R&D Management Co., Ltd. | Amorphous form of quinoline derivative, and method for producing same |
| CA2901280A1 (en) | 2013-02-15 | 2014-08-21 | Allergan, Inc. | Sustained drug delivery implant |
| CN105264380B (zh) | 2013-05-14 | 2017-09-05 | 卫材R&D管理有限公司 | 用于预测和评价子宫内膜癌受试者对乐伐替尼化合物响应性的生物标志 |
| EP3012248B1 (en) | 2013-06-20 | 2019-09-11 | Institute of Radiation Medicine, Academy of Military Medical Sciences, People's Liberation Army of China | Substance having tyrosine kinase inhibitory activity and preparation method and use thereof |
| CA2957005C (en) | 2014-08-28 | 2021-10-12 | Eisai R&D Management Co., Ltd. | High-purity quinoline derivative and method for manufacturing same |
| SG11201706630UA (en) | 2015-02-25 | 2017-09-28 | Eisai R&D Man Co Ltd | Method for suppressing bitterness of quinoline derivative |
| WO2016140717A1 (en) | 2015-03-04 | 2016-09-09 | Merck Sharp & Dohme Corp. | Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer |
| BR112017027227B1 (pt) | 2015-06-16 | 2023-12-12 | Eisai R&D Management Co., Ltd | Agente anti-câncer |
| JP6553726B2 (ja) | 2015-08-20 | 2019-07-31 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療剤 |
| US12303505B2 (en) | 2017-02-08 | 2025-05-20 | Eisai R&D Management Co., Ltd. | Tumor-treating pharmaceutical composition |
| CN108822017A (zh) * | 2017-04-11 | 2018-11-16 | 中国医学科学院药物研究所 | 新型吲哚酮化合物及其制法和药物用途 |
| BR112019023064A2 (pt) | 2017-05-16 | 2020-06-09 | Eisai R&D Man Co Ltd | tratamento de carcinoma hepatocelular |
| SG11202103459WA (en) * | 2018-10-05 | 2021-05-28 | Ichnos Sciences S A | Indolinone compounds for use as map4k1 inhibitors |
| CN111285872B (zh) * | 2018-12-06 | 2022-05-17 | 北京志健金瑞生物医药科技有限公司 | 吲哚-2-酮衍生物及其制备方法与用途 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4476307A (en) * | 1982-09-20 | 1984-10-09 | Pfizer Inc. | Heteroylidene indolone compounds |
| US4966849A (en) * | 1985-09-20 | 1990-10-30 | President And Fellows Of Harvard College | CDNA and genes for human angiogenin (angiogenesis factor) and methods of expression |
| US5217999A (en) * | 1987-12-24 | 1993-06-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Styryl compounds which inhibit EGF receptor protein tyrosine kinase |
| AT389506B (de) * | 1988-08-04 | 1989-12-27 | Voest Alpine Maschinenbau | Verfahren und vorrichtung zum graphitieren von kohlenstoffkoerpern |
| WO1991015495A1 (en) | 1990-04-02 | 1991-10-17 | Pfizer Inc. | Benzylphosphonic acid tyrosine kinase inhibitors |
| US5302606A (en) * | 1990-04-16 | 1994-04-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase |
| CA2102780C (en) | 1991-05-10 | 2007-01-09 | Alfred P. Spada | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
| CA2108889A1 (en) | 1991-05-29 | 1992-11-30 | Robert Lee Dow | Tricyclic polyhydroxylic tyrosine kinase inhibitors |
| CA2140440A1 (en) | 1992-08-06 | 1994-02-17 | Ellen M. Dobrusin | 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties |
| US5330992A (en) * | 1992-10-23 | 1994-07-19 | Sterling Winthrop Inc. | 1-cyclopropyl-4-pyridyl-quinolinones |
| DK1975181T3 (da) | 1992-10-28 | 2011-06-06 | Genentech Inc | Anvendelse af vaskulære endothelcelle-vækstfaktor-antagonister |
| GB9226855D0 (en) | 1992-12-23 | 1993-02-17 | Erba Carlo Spa | Vinylene-azaindole derivatives and process for their preparation |
| US6316635B1 (en) * | 1995-06-07 | 2001-11-13 | Sugen, Inc. | 2-indolinone derivatives as modulators of protein kinase activity |
| US5880141A (en) * | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| GB9718913D0 (en) * | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
| DE19824922A1 (de) * | 1998-06-04 | 1999-12-09 | Boehringer Ingelheim Pharma | Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel |
| EP1117397A1 (en) | 1998-08-31 | 2001-07-25 | Sugen, Inc. | Geometrically restricted 2-indolinone derivatives as modulators of protein kinase activity |
| EE200100184A (et) * | 1998-09-25 | 2002-08-15 | Boehringer Ingelheim Pharma Kg | Uudsed asendatud indolinoonid inhibeeriva toimegamitmesugustele kinaasidele ja tsükliin/CDK kompleksidele |
| GB9904933D0 (en) * | 1999-03-04 | 1999-04-28 | Glaxo Group Ltd | Compounds |
| JP3952369B2 (ja) * | 1999-08-27 | 2007-08-01 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | 新規な置換インドリノン類、その製造及びその薬剤としての使用 |
| UA75054C2 (uk) * | 1999-10-13 | 2006-03-15 | Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг | Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу |
| US6762180B1 (en) * | 1999-10-13 | 2004-07-13 | Boehringer Ingelheim Pharma Kg | Substituted indolines which inhibit receptor tyrosine kinases |
| AU2001288374A1 (en) * | 2000-09-01 | 2002-03-22 | Glaxo Group Limited | Substituted oxindole derivatives as tyrosine kinase inhibitors |
| US20030225152A1 (en) * | 2001-09-27 | 2003-12-04 | Andrews Steven W. | 3-(Arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors |
-
2002
- 2002-09-27 US US10/259,703 patent/US20030225152A1/en not_active Abandoned
- 2002-09-27 CA CA2461812A patent/CA2461812C/en not_active Expired - Fee Related
- 2002-09-27 EP EP02776036A patent/EP1430048A1/en not_active Withdrawn
- 2002-09-27 WO PCT/US2002/030882 patent/WO2003027102A1/en not_active Ceased
- 2002-09-27 AU AU2002341881A patent/AU2002341881B2/en not_active Ceased
- 2002-09-27 JP JP2003530690A patent/JP2005508336A/ja active Pending
- 2002-09-27 US US10/256,879 patent/US6765012B2/en not_active Expired - Fee Related
-
2004
- 2004-02-20 US US10/783,325 patent/US7015220B2/en not_active Expired - Lifetime
- 2004-07-06 US US10/886,213 patent/US7098236B2/en not_active Expired - Lifetime
-
2005
- 2005-09-16 US US11/228,780 patent/US20060025413A1/en not_active Abandoned
- 2005-11-15 US US11/274,681 patent/US7414054B2/en not_active Expired - Lifetime
-
2006
- 2006-03-31 US US11/396,036 patent/US20060194863A1/en not_active Abandoned
-
2010
- 2010-01-25 JP JP2010013326A patent/JP2010116411A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2461812A1 (en) | 3-(arylamino)methylene-1,3-dihydro-2h-indol-2-ones as kinase inhibitors | |
| US6090807A (en) | Use of heterocyclic compounds | |
| JP6728208B2 (ja) | ベンザゼピンジカルボキサミド化合物 | |
| US6232327B1 (en) | Indolyl-3-glyoxylic acid derivatives having antitumor action | |
| CN103124730B (zh) | 杂环炔苯类化合物及其药用组合物和应用 | |
| JP6506779B2 (ja) | 医薬化合物 | |
| JP5886411B2 (ja) | 新規のピリミジン誘導体 | |
| RU2386630C2 (ru) | Соединения и композиции в качестве ингибиторов протеинтирозинкиназы | |
| RU2006137716A (ru) | Ингибиторы гистондеацетилазы | |
| RU2003115429A (ru) | Производные имида индолилмалеиновой кислоты как ингибиторы протеинкиназы с | |
| CA2529734A1 (en) | 2-amino-4-hydroxy-5-pyrimidine carboxamide derivatives and related compounds as inhibitors of t cell activation for the treatment of inflammatory diseases | |
| JP2012512886A5 (enExample) | ||
| TR201816387T4 (tr) | Bisiklik heterosikllerin antiviral aktivitesi. | |
| JP2013526511A (ja) | 医薬化合物 | |
| JP2005508967A5 (enExample) | ||
| SI2961736T1 (en) | Histone demethylase inhibitors | |
| US11001581B2 (en) | Compounds which inhibit RNA polymerase, compositions including such compounds, and their use | |
| EP2776407A1 (en) | Modulators of the g protein-coupled mas receptor and the treatment of disorders related thereto | |
| WO2009121535A2 (en) | Antiproliferative compounds and therapeutic uses thereof | |
| CA2997039A1 (en) | 2,4-bis(nitrogen-containing group)-substituted pyrimidine compound, preparation method and use thereof | |
| CA2617991A1 (en) | N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof | |
| RU2009119181A (ru) | Гетероциклические соединения и их применение в качестве ингибиторов гликогенсинтаза-киназы-3 | |
| RU2149872C1 (ru) | Пиридилтиосоединения для борьбы с бактериями helicobacter | |
| RU2011105059A (ru) | Применение производных пиримидиламинобензамида для лечения фиброза | |
| CN110437220B (zh) | 三氮唑类化合物及其应用 |